These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17895068)

  • 21. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database.
    Nagel S; Wang X; Carcel C; Robinson T; Lindley RI; Chalmers J; Anderson CS;
    Stroke; 2018 Jun; 49(6):1407-1411. PubMed ID: 29777016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical recovery and health-related quality of life in ischaemic stroke survivors receiving thrombolytic treatment: a 1-year follow-up study.
    Grabowska-Fudala B; Jaracz K; Górna K; Jaracz J; Kaźmierski R
    J Thromb Thrombolysis; 2017 Jan; 43(1):91-97. PubMed ID: 27613176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing contents of functional outcome measures in stroke rehabilitation using the International Classification of Functioning, Disability and Health.
    Schepers VP; Ketelaar M; van de Port IG; Visser-Meily JM; Lindeman E
    Disabil Rehabil; 2007 Feb; 29(3):221-30. PubMed ID: 17364773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Stroke Unit Care in Acute Ischemic Stroke Patient Ineligible for Thrombolytic Treatment.
    Rajborirug K; Tumviriyakul H; Suwanno J
    J Med Assoc Thai; 2017 Apr; 100(4):410-7. PubMed ID: 29911837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in patients with TIA and minor ischemic stroke.
    Sangha RS; Caprio FZ; Askew R; Corado C; Bernstein R; Curran Y; Ruff I; Cella D; Naidech AM; Prabhakaran S
    Neurology; 2015 Dec; 85(22):1957-63. PubMed ID: 26537051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome and safety assessment of an herbal medicine treatment protocol for yin pattern of acute ischemic stroke.
    Huang Y; Guo JW;
    Zhong Xi Yi Jie He Xue Bao; 2010 May; 8(5):417-26. PubMed ID: 20456839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A critical appraisal of stroke evaluation and rating scales.
    Lyden PD; Lau GT
    Stroke; 1991 Nov; 22(11):1345-52. PubMed ID: 1750040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining post-stroke recovery: implications for design and interpretation of drug trials.
    Duncan PW; Lai SM; Keighley J
    Neuropharmacology; 2000 Mar; 39(5):835-41. PubMed ID: 10699448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
    Feng W; Vasquez G; Suri MF; Lakshminarayan K; Qureshi AI
    J Stroke Cerebrovasc Dis; 2011; 20(3):241-6. PubMed ID: 20621509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators.
    Saver JL; Johnston KC; Homer D; Wityk R; Koroshetz W; Truskowski LL; Haley EC
    Stroke; 1999 Feb; 30(2):293-8. PubMed ID: 9933262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Threshold for NIH stroke scale in predicting vessel occlusion and functional outcome after stroke thrombolysis.
    Cooray C; Fekete K; Mikulik R; Lees KR; Wahlgren N; Ahmed N
    Int J Stroke; 2015 Aug; 10(6):822-9. PubMed ID: 25588617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis.
    Banks JL; Marotta CA
    Stroke; 2007 Mar; 38(3):1091-6. PubMed ID: 17272767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenging comparison of stroke scales.
    Ghandehari K
    J Res Med Sci; 2013 Oct; 18(10):906-10. PubMed ID: 24497865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke.
    Hong KS; Saver JL
    Stroke; 2010 Mar; 41(3):471-7. PubMed ID: 20133917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
    Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
    J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.